Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2026. The quarterly dividend will be payable November 23, 2026, to all common shareholders of record at the close of bu

Bio-Techne Corporation Declares Quarterly Dividend of $0.08 Per Share

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Lennox International Inc (Symbol: LII) has taken over the #464 spot from Bio-Techne Corp (Symbol: TECH), according to The Online Investor.  

	Market capitalization is an

Lennox International Moves Up In Market Cap Rank, Passing Bio-Techne 

INCY vs. TECH: Which Stock Is the Better Value Option?

INCY or TECH: Which Is the Better Value Stock Right Now?

Insider reported a trade at BIO-TECHNE Corp

Bio-Techne Corporation (NASDAQ:TECH) shareholders voted on September 23 to approve the company’s acquisition by Merck KGaA of Darmstadt, Germany. The German group is paying $73 a share in cash, valuing the business at about $11.3 billion including debt. They also voted down the executive compensation proposal attached to the deal, which is an unusual pairing. […]

Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package

Bio-Techne has outperformed the Nasdaq over the past year, but analysts are cautious about the stock’s prospects.

Is Bio-Techne Stock Outperforming the Nasdaq?

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corporation News